GrOwnValve GmbH
- Industry
- Medical Devices
- Founded Year
- 2019
- Headquarters
- Seestrae 13, 13353 Berlin, Germany
- Employee Count
- 14
Key People
- PD Dr. Boris Schmitt, MD, PhD - Managing Director
- Jasper Emeis - Business Administration
- Jordi Modolell - Product Manager
- Alexander Breitenstein - Engineer 3D Technology
- Marvin Steitz - Toxicologist
- Moritz Stroehle - Studentischer Mitarbeiter Engineering
- Eugenia Weber - Research and Development Engineer
- Carlo Wentzel - Computational Engineer
- Yasir AL-Asadi - Software Engineer | ML Engineer
- Mahamuda Khan - Medical Biotechnology | Research
- Katrin Schrimpf - Veterinarian
- Aileen Grabowski - Quality Management | Regulatory Affairs (QMR)
- Johanna Ticar - Project Management
- Florence Kosche - Research and Development Engineer
- Axel Mewes - Human Resources
- Peter Khalil - Working Student
Assessment
- Team
-
Aspect: First-time physician innovator
Summary: The leadership team, including Dr. Boris Schmitt and Jasper Emeis, brings a blend of medical and business expertise, crucial for MedTech innovation.
The combination of medical and business backgrounds in the leadership team positions GrOwnValve well for navigating the complexities of medical device development and commercialization.
- Clinical Need
-
Aspect: Very Strong
Summary: GrOwnValve addresses a significant unmet need for durable, personalized heart valve prostheses, especially in pediatric patients.
By developing heart valves from patients' own tissue, GrOwnValve aims to reduce the need for repeated surgeries and lifelong medication, offering a potentially transformative solution in cardiac care.
- Competition
-
Aspect: First mover
Summary: GrOwnValve's approach to autologous heart valves is pioneering, with limited direct competition in this specific niche.
While traditional heart valve manufacturers exist, GrOwnValve's unique method of using patient-derived tissue sets it apart, potentially offering a competitive advantage.
- Technical Challenge
-
Aspect: Very Complex
Summary: Developing personalized, bioresorbable heart valves involves significant technical and regulatory challenges.
The integration of medical imaging, 3D printing, and biocompatible materials to create patient-specific implants is a complex endeavor requiring multidisciplinary expertise.
- Patent
-
Aspect: Very Strong
Summary: GrOwnValve holds multiple patents in the field of medical devices, indicating a strong intellectual property position.
A robust patent portfolio can provide competitive protection and potential licensing opportunities, enhancing the company's market position.
- Financing
-
Aspect: Well-funded
Summary: GrOwnValve has secured significant funding from reputable sources, including the European Innovation Council.
Adequate funding supports continued research, development, and clinical trials, which are essential for bringing innovative medical devices to market.
- Regulatory
-
Aspect: Running FIH
Summary: GrOwnValve has initiated first-in-human clinical trials, a critical step in the regulatory approval process.
Progressing to human trials demonstrates the company's commitment to validating safety and efficacy, moving closer to potential market approval.
Opportunity Rollup
- Odds of Success
- 3
- Peak Market Share
- 3.55
- Segment CAGR
- 15.1%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Transcatheter Heart Valves
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.18 |
| 2 | 0.53 |
| 3 | 1.24 |
| 4 | 2.48 |
| 5 | 3.55 |
Key Takeaway
GrOwnValve's innovative approach to personalized heart valve prostheses addresses a significant clinical need, positioning the company favorably in a growing market segment.